nach oben

Cancer and Metastasis Reviews

Erschienen in:

22.06.2018

Bioanalytical insights into the association between eicosanoids and pathogenesis of hepatocellular carcinoma

verfasst von: Yong-Jiang Xu, Zhaojun Zheng, Chen Cao, Jinwei Li, Yuanfa Liu

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2-3/2018

Einloggen, um Zugang zu erhalten

Abstract

It has been noted that inflammatory were intimately associated with the development and progression of hepatocellular carcinoma (HCC). Eicosanoids derived from arachidonic acid play crucial roles in chronic inflammation. Accordingly, there is an intricate relationship between eicosanoids and HCC, being supported by the epidemiological, clinical, and basic science studies. Herein, we intend to provide bioanalytical insights into the role of eicosanoids in HCC progression, from cell proliferation, angiogenesis migration, to apoptosis. Also, the analytical methods and biochemistry of eicosanoids are described.

Dupre, A., & Malik, H. Z. (2018). Inflammation and cancer: what a surgical oncologist should know. European Journal of Surgical Oncology, 44, 566–570. https://doi.org/10.1016/j.ejso.2018.02.209.CrossRefPubMed

Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., Li, Y., Wang, X., & Zhao, L. (2018). Inflammatory responses and inflammation-associated diseases in organs. Oncotarget, 9(6), 7204–7218. https://doi.org/10.18632/oncotarget.23208.PubMedCrossRef

Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., & Hermoso, M. A. (2014). Chronic inflammation and cytokines in the tumor microenvironment. Journal of Immunology Research, 2014, 149185–149119. https://doi.org/10.1155/2014/149185.CrossRefPubMedPubMedCentral

Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA: a Cancer Journal for Clinicians, 61(2), 69–90. https://doi.org/10.3322/caac.20107.CrossRef

Erkekoglu, P., Oral, D., Chao, M. W., & Kocer-Gumusel, B. (2017). Hepatocellular carcinoma and possible chemical and biological causes: a review. Journal of Environmental Pathology, Toxicology and Oncology, 36(2), 171–190. https://doi.org/10.1615/JEnvironPatholToxicolOncol.2017020927.CrossRefPubMed

Huan, L., Liang, L. H., & He, X. H. (2016). Role of microRNAs in inflammation-associated liver cancer. Cancer Biology and Medicine, 13(4), 407–425. https://doi.org/10.20892/j.issn.2095-3941.2016.0071.CrossRefPubMed

Chiurchiu, V., Leuti, A., & Maccarrone, M. (2018). Bioactive lipids and chronic inflammation: managing the fire within. Frontiers in Immunology, 9, 38. https://doi.org/10.3389/fimmu.2018.00038.CrossRefPubMedPubMedCentral

Dennis, E. A., & Norris, P. C. (2015). Eicosanoid storm in infection and inflammation. Nature Reviews. Immunology, 15(8), 511–523. https://doi.org/10.1038/nri3859.CrossRefPubMedPubMedCentral

Liu, Y., Li, H., Zhao, C., & Jia, H. (2018). MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma. Molecular and Cellular Biochemistry. https://doi.org/10.1007/s11010-018-3313-0.

10.

Luz, C. C. F., Noguti, J., Araujo, L., Simao Gomes, T., Mara, G., Silva, M. S., et al. (2018). Expression of VEGF and Cox-2 in patients with esophageal squamous cell carcinoma. Asian Pacific Journal of Cancer Prevention, 19(1), 171–177. https://doi.org/10.22034/APJCP.2018.19.1.171.PubMedCrossRef

11.

Anadol, E., Yar Saglam, A. S., Gultiken, N., Karakas, K., Alcigir, E., Alkan, H., & Kanca, H. (2017). Expression of iNOS, COX-2 and VEGF in canine mammary tumours and non-neoplastic mammary glands: association with clinicopathological features and tumour grade. Acta Veterinaria Hungarica, 65(3), 382–393. https://doi.org/10.1556/004.2017.036.CrossRefPubMed

12.

Wu, T. (2006). Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treatment Reviews, 32(1), 28–44. https://doi.org/10.1016/j.ctrv.2005.10.004.CrossRefPubMed

13.

Breinig, M., Schirmacher, P., & Kern, M. A. (2007). Cyclooxygenase-2 (COX-2)—a therapeutic target in liver cancer? Current Pharmaceutical Design, 13(32), 3305–3315.CrossRefPubMed

14.

Gautam, S., Roy, S., Ansari, M. N., Saeedan, A. S., Saraf, S. A., & Kaithwas, G. (2017). DuCLOX-2/5 inhibition: a promising target for cancer chemoprevention. Breast Cancer, 24(2), 180–190. https://doi.org/10.1007/s12282-016-0723-2.CrossRefPubMed

15.

Mashima, R., & Okuyama, T. (2015). The role of lipoxygenases in pathophysiology; new insights and future perspectives. Redox Biology, 6, 297–310. https://doi.org/10.1016/j.redox.2015.08.006.CrossRefPubMedPubMedCentral

16.

D'Uva, G., Baci, D., Albini, A., & Noonan, D. M. (2018). Cancer chemoprevention revisited: cytochrome P450 family 1B1 as a target in the tumor and the microenvironment. Cancer Treatment Reviews, 63, 1–18. https://doi.org/10.1016/j.ctrv.2017.10.013.CrossRefPubMed

17.

Johnson, A. L., Edson, K. Z., Totah, R. A., & Rettie, A. E. (2015). Cytochrome P450 omega-hydroxylases in inflammation and cancer. Advances in Pharmacology, 74, 223–262. https://doi.org/10.1016/bs.apha.2015.05.002.CrossRefPubMed

18.

Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nature Reviews. Cancer, 10(3), 181–193. https://doi.org/10.1038/nrc2809.CrossRefPubMedPubMedCentral

19.

Tuncer, S., & Banerjee, S. (2015). Eicosanoid pathway in colorectal cancer: recent updates. World Journal of Gastroenterology, 21(41), 11748–11766. https://doi.org/10.3748/wjg.v21.i41.11748.CrossRefPubMedPubMedCentral

20.

Moore, G. Y., & Pidgeon, G. P. (2017). Cross-talk between cancer cells and the tumour microenvironment: the role of the 5-lipoxygenase pathway. International Journal of Molecular Sciences, 18(2). https://doi.org/10.3390/ijms18020236.

21.

Kasuga, K., Suga, T., & Mano, N. (2015). Bioanalytical insights into mediator lipidomics. Journal of Pharmaceutical and Biomedical Analysis, 113, 151–162. https://doi.org/10.1016/j.jpba.2015.02.011.CrossRefPubMed

22.

Gong, Z. G., Hu, J., Wu, X., & Xu, Y. J. (2017). The recent developments in sample preparation for mass spectrometry-based metabolomics. Critical Reviews in Analytical Chemistry, 47(4), 325–331. https://doi.org/10.1080/10408347.2017.1289836.CrossRefPubMed

23.

Maskrey, B. H., & O'Donnell, V. B. (2008). Analysis of eicosanoids and related lipid mediators using mass spectrometry. Biochemical Society Transactions, 36(Pt 5), 1055–1059. https://doi.org/10.1042/BST0361055. CrossRefPubMed

24.

Morgenstern, J., Fleming, T., Kadiyska, I., Brings, S., Groener, J. B., Nawroth, P., Hecker, M., & Brune, M. (2018). Sensitive mass spectrometric assay for determination of 15-deoxy-Delta(12,14)-prostaglandin J2 and its application in human plasma samples of patients with diabetes. Analytical and Bioanalytical Chemistry, 410(2), 521–528. https://doi.org/10.1007/s00216-017-0748-1.CrossRefPubMed

25.

Bian, Q., Wang, W., Wang, N., Peng, Y., Ma, W., & Dai, R. (2016). Quantification of arachidonic acid and its metabolites in rat tissues by UHPLC-MS/MS: application for the identification of potential biomarkers of benign prostatic hyperplasia. PLoS One, 11(11), e0166777. https://doi.org/10.1371/journal.pone.0166777.CrossRefPubMedPubMedCentral

26.

Ostermann, A. I., Willenberg, I., & Schebb, N. H. (2015). Comparison of sample preparation methods for the quantitative analysis of eicosanoids and other oxylipins in plasma by means of LC-MS/MS. Analytical and Bioanalytical Chemistry, 407(5), 1403–1414. https://doi.org/10.1007/s00216-014-8377-4.CrossRefPubMed

27.

Fernandez-Peralbo, M. A., Ferreiro Vera, C., Priego-Capote, F., & Luque de Castro, M. D. (2014). Stable isotopic internal standard correction for quantitative analysis of hydroxyeicosatetraenoic acids (HETEs) in serum by on-line SPE-LC-MS/MS in selected reaction monitoring mode. Talanta, 126, 170–176. https://doi.org/10.1016/j.talanta.2014.03.038.CrossRefPubMed

28.

Bessonneau, V., Zhan, Y., De Lannoy, I. A., Saldivia, V., & Pawliszyn, J. (2015). In vivo solid-phase microextraction liquid chromatography-tandem mass spectrometry for monitoring blood eicosanoids time profile after lipopolysaccharide-induced inflammation in Sprague-Dawley rats. Journal of Chromatography. A, 1424, 134–138. https://doi.org/10.1016/j.chroma.2015.10.067.CrossRefPubMed

29.

Chen, C. Y., Lin, P., Tsai, M. H., & Lee, H. L. (2017). Targeted lipidomics profiling of acute arsenic exposure in mice serum by on-line solid-phase extraction stable-isotope dilution liquid chromatography-tandem mass spectrometry. Archives of Toxicology, 91(9), 3079–3091. https://doi.org/10.1007/s00204-017-1937-6.CrossRefPubMed

30.

Ferreiro-Vera, C., Mata-Granados, J. M., Priego-Capote, F., Quesada-Gomez, J. M., & Luque de Castro, M. D. (2011). Automated targeting analysis of eicosanoid inflammation biomarkers in human serum and in the exometabolome of stem cells by SPE-LC-MS/MS. Analytical and Bioanalytical Chemistry, 399(3), 1093–1103. https://doi.org/10.1007/s00216-010-4400-6.CrossRefPubMed

31.

Tsikas, D., & Zoerner, A. A. (2014). Analysis of eicosanoids by LC-MS/MS and GC-MS/MS: a historical retrospect and a discussion. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 964, 79–88. https://doi.org/10.1016/j.jchromb.2014.03.017.CrossRefPubMed

32.

Bystricka, Z., & Durackova, Z. (2016). Gas chromatography determination of fatty acids in the human erythrocyte membranes—a review. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 115, 35–40. https://doi.org/10.1016/j.plefa.2016.09.007.CrossRefPubMed

33.

Jiang, H., McGiff, J. C., Quilley, J., Sacerdoti, D., Reddy, L. M., Falck, J. R., Zhang, F., Lerea, K. M., & Wong, P. Y. K. (2004). Identification of 5,6-trans-epoxyeicosatrienoic acid in the phospholipids of red blood cells. The Journal of Biological Chemistry, 279(35), 36412–36418. https://doi.org/10.1074/jbc.M403962200.CrossRefPubMed

34.

Yen, H. C., Wei, H. J., & Lin, C. L. (2015). Unresolved issues in the analysis of F2-isoprostanes, F4-neuroprostanes, isofurans, neurofurans, and F2-dihomo-isoprostanes in body fluids and tissue using gas chromatography/negative-ion chemical-ionization mass spectrometry. Free Radical Research, 49(7), 861–880. https://doi.org/10.3109/10715762.2015.1014812.CrossRefPubMed

35.

Kortz, L., Dorow, J., & Ceglarek, U. (2014). Liquid chromatography-tandem mass spectrometry for the analysis of eicosanoids and related lipids in human biological matrices: a review. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 964, 1–11. https://doi.org/10.1016/j.jchromb.2014.01.046.CrossRefPubMed

36.

Dalli, J., Colas, R. A., Walker, M. E., & Serhan, C. N. (2018). Lipid mediator metabolomics via LC-MS/MS profiling and analysis. Methods in Molecular Biology, 1730, 59–72. https://doi.org/10.1007/978-1-4939-7592-1_4.CrossRefPubMed

37.

Lee, Y. Y., Galano, J. M., Oger, C., Vigor, C., Guillaume, R., Roy, J., le Guennec, J. Y., Durand, T., & Lee, J. C. Y. (2016). Assessment of isoprostanes in human plasma: technical considerations and the use of mass spectrometry. Lipids, 51(11), 1217–1229. https://doi.org/10.1007/s11745-016-4198-x.CrossRefPubMed

38.

Meckelmann, S. W., Hellhake, S., Steuck, M., Krohn, M., & Schebb, N. H. (2017). Comparison of derivatization/ionization techniques for liquid chromatography tandem mass spectrometry analysis of oxylipins. Prostaglandins & Other Lipid Mediators, 130, 8–15. https://doi.org/10.1016/j.prostaglandins.2017.02.003.CrossRef

39.

Liu, X., Moon, S. H., Mancuso, D. J., Jenkins, C. M., Guan, S., Sims, H. F., & Gross, R. W. (2013). Oxidized fatty acid analysis by charge-switch derivatization, selected reaction monitoring, and accurate mass quantitation. Analytical Biochemistry, 442(1), 40–50. https://doi.org/10.1016/j.ab.2013.06.014.CrossRefPubMed

40.

Agundez, J. A., Blanca, M., Cornejo-Garcia, J. A., & Garcia-Martin, E. (2015). Pharmacogenomics of cyclooxygenases. Pharmacogenomics, 16(5), 501–522. https://doi.org/10.2217/pgs.15.6.CrossRefPubMed

41.

Willoughby, D. A., Moore, A. R., & Colville-Nash, P. R. (2000). COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet, 355(9204), 646–648. https://doi.org/10.1016/S0140-6736(99)12031-2.CrossRefPubMed

42.

Salinas, G., Rangasetty, U. C., Uretsky, B. F., & Birnbaum, Y. (2007). The cycloxygenase 2 (COX-2) story: it’s time to explain, not inflame. Journal of Cardiovascular Pharmacology and Therapeutics, 12(2), 98–111. https://doi.org/10.1177/1074248407301172.CrossRefPubMed

43.

Sugita, R., Kuwabara, H., Kubota, K., Sugimoto, K., Kiho, T., Tengeiji, A., Kawakami, K., & Shimada, K. (2016). Simultaneous inhibition of PGE2 and PGI2 signals is necessary to suppress hyperalgesia in rat inflammatory pain models. Mediators of Inflammation, 2016, 9847840. https://doi.org/10.1155/2016/9847840.CrossRefPubMedPubMedCentral

44.

Hovsepian, E., Penas, F., & Goren, N. B. (2010). 15-deoxy-Delta12,14 prostaglandin GJ2 but not rosiglitazone regulates metalloproteinase 9, NOS-2, and cyclooxygenase 2 expression and functions by peroxisome proliferator-activated receptor gamma-dependent and -independent mechanisms in cardiac cells. Shock, 34(1), 60–67. https://doi.org/10.1097/SHK.0b013e3181cdc398.CrossRefPubMed

45.

Vazzana, N., Santilli, F., Lattanzio, S., Liani, M., Giacci, L., Del Rosso, G., et al. (2016). Determinants of thromboxane biosynthesis in patients with moderate to severe chronic kidney disease. European Journal of Internal Medicine, 33, 74–80. https://doi.org/10.1016/j.ejim.2016.06.016.CrossRefPubMed

46.

Im, D. S. (2009). New intercellular lipid mediators and their GPCRs: an update. Prostaglandins & Other Lipid Mediators, 89(3–4), 53–56. https://doi.org/10.1016/j.prostaglandins.2009.01.002.CrossRef

47.

Peinhaupt, M., Sturm, E. M., & Heinemann, A. (2017). Prostaglandins and their receptors in eosinophil function and as therapeutic targets. Front Med (Lausanne), 4, 104. https://doi.org/10.3389/fmed.2017.00104.CrossRef

48.

Theoleyre, S., Mottier, S., Masson, D., & Denis, M. G. (2010). HtrA3 is regulated by 15-deoxy-Delta12,14-prostaglandin J2 independently of PPARgamma in clear cell renal cell carcinomas. Biochemical and Biophysical Research Communications, 394(3), 453–458. https://doi.org/10.1016/j.bbrc.2009.11.163.CrossRefPubMed

49.

Samodelkin, E. I., Mercucheva, N. G., Kosareva, P. V., & Nesterova, L. Y. (2017). The role of prostaglandins and cyclooxygenase in pathogenesis of chronic endometritis. Patologicheskaia Fiziologiia i Èksperimental'naia Terapiia, 61(2), 98–100.PubMed

50.

Babenko, L. M., Shcherbatiuk, M. M., Skaterna, T. D., & Kosakivska, I. V. (2017). Lipoxygenases and their metabolites in formation of plant stress tolerance. Ukrainian Biochemical Journal, 89(1), 5–21. https://doi.org/10.15407/ubj89.01.005.CrossRefPubMed

51.

Radmark, O., Werz, O., Steinhilber, D., & Samuelsson, B. (2015). 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochimica et Biophysica Acta, 1851(4), 331–339. https://doi.org/10.1016/j.bbalip.2014.08.012.CrossRefPubMed

52.

Ackermann, J. A., Hofheinz, K., Zaiss, M. M., & Kronke, G. (2017). The double-edged role of 12/15-lipoxygenase during inflammation and immunity. Biochimica et Biophysica Acta, 1862(4), 371–381. https://doi.org/10.1016/j.bbalip.2016.07.014.CrossRefPubMed

53.

Wan, M., Tang, X., Stsiapanava, A., & Haeggstrom, J. Z. (2017). Biosynthesis of leukotriene B4. Seminars in Immunology, 33, 3–15. https://doi.org/10.1016/j.smim.2017.07.012. CrossRefPubMed

54.

Powell, W. S., & Rokach, J. (2015). Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid. Biochimica et Biophysica Acta, 1851(4), 340–355. https://doi.org/10.1016/j.bbalip.2014.10.008.CrossRefPubMed

55.

Cornejo-Garcia, J. A., Perkins, J. R., Jurado-Escobar, R., Garcia-Martin, E., Agundez, J. A., Viguera, E., et al. (2016). Pharmacogenomics of prostaglandin and leukotriene receptors. Frontiers in Pharmacology, 7, 316. https://doi.org/10.3389/fphar.2016.00316.CrossRefPubMedPubMedCentral

56.

Stavropoulou, E., Pircalabioru, G. G., & Bezirtzoglou, E. (2018). The role of cytochromes P450 in infection. Frontiers in Immunology, 9, 89. https://doi.org/10.3389/fimmu.2018.00089.CrossRefPubMedPubMedCentral

57.

Fan, F., & Roman, R. J. (2017). Effect of cytochrome P450 metabolites of arachidonic acid in nephrology. J Am Soc Nephrol, 28(10), 2845–2855. https://doi.org/10.1681/ASN.2017030252.CrossRefPubMedPubMedCentral

58.

Wei, X., Zhang, D., Dou, X., Niu, N., Huang, W., Bai, J., & Zhang, G. (2014). Elevated 14,15-epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer. BMC Cancer, 14, 841. https://doi.org/10.1186/1471-2407-14-841.CrossRefPubMedPubMedCentral

59.

Jamieson, K. L., Endo, T., Darwesh, A. M., Samokhvalov, V., & Seubert, J. M. (2017). Cytochrome P450-derived eicosanoids and heart function. Pharmacology & Therapeutics, 179, 47–83. https://doi.org/10.1016/j.pharmthera.2017.05.005.CrossRef

60.

Yuan, L., Liu, J., Dong, R., Zhu, J., Tao, C., Zheng, R., & Zhu, S. (2016). 14,15-epoxyeicosatrienoic acid promotes production of brain derived neurotrophic factor from astrocytes and exerts neuroprotective effects during ischaemic injury. Neuropathology and Applied Neurobiology, 42(7), 607–620. https://doi.org/10.1111/nan.12291.CrossRefPubMed

61.

Wang, D., Hirase, T., Nitto, T., Soma, M., & Node, K. (2009). Eicosapentaenoic acid increases cytochrome P-450 2J2 gene expression and epoxyeicosatrienoic acid production via peroxisome proliferator-activated receptor gamma in endothelial cells. Journal of Cardiology, 54(3), 368–374. https://doi.org/10.1016/j.jjcc.2009.06.004.CrossRefPubMed

62.

Qiu, D. K., Ma, X., Peng, Y. S., & Chen, X. Y. (2002). Significance of cyclooxygenase-2 expression in human primary hepatocellular carcinoma. World Journal of Gastroenterology, 8(5), 815–817.CrossRefPubMedPubMedCentral

63.

Cheng, A. S., Chan, H. L., Leung, W. K., Wong, N., Johnson, P. J., & Sung, J. J. (2003). Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells. International Journal of Oncology, 23(1), 113–119.PubMed

64.

Leng, J., Han, C., Demetris, A. J., Michalopoulos, G. K., & Wu, T. (2003). Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology, 38(3), 756–768. https://doi.org/10.1053/jhep.2003.50380.CrossRefPubMed

65.

Qinglin, L., Xin, W., Zhong, L., Fang, L., Cao, G., & Huang, P. (2017). A study on the anti-tumor mechanism of total flavonoids from Radix Tetrastigmae against additional cell line based on COX-2-mediated Wnt/beta-catenin signaling pathway. Oncotarget, 8(33), 54304–54319. https://doi.org/10.18632/oncotarget.16876. CrossRefPubMedPubMedCentral

66.

Hamzawy, M., Elsaid, L., Shams, A., Rashid, L., Mahfouz, S., & Sharawy, N. (2015). Study of the effects of cyclooxygenase-2 inhibitor on the promotion of hepatic tumorigenesis in rats fed a high fat diet. J Clin Exp Hepatol, 5(1), 14–21. https://doi.org/10.1016/j.jceh.2014.12.010.CrossRefPubMedPubMedCentral

67.

Dong, R. Z., Dong, F. X., Liu, Q. T., Zhi, T. X., Zou, J., Zhong, T. J., et al. (2018). COX-2/PGE2 Axis regulates HIF-2alpha activity to promote hepatocellular carcinoma hypoxic response and reduce the sensitivity of sorafenib treatment. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-17-2725.

68.

Xu, G., Wang, Y., Li, W., Cao, Y., Xu, J., Hu, Z., Hao, Y., Hu, L., & Sun, Y. (2018). COX-2 forms regulatory loop with YAP to promote proliferation and tumorigenesis of hepatocellular carcinoma cells. Neoplasia, 20(4), 324–334. https://doi.org/10.1016/j.neo.2017.12.004.CrossRefPubMedPubMedCentral

69.

Chen, H., Cai, W., Chu, E. S. H., Tang, J., Wong, C. C., Wong, S. H., Sun, W., Liang, Q., Fang, J., Sun, Z., & Yu, J. (2017). Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice. Oncogene, 36(31), 4415–4426. https://doi.org/10.1038/onc.2017.73.CrossRefPubMedPubMedCentral

70.

Yang, H. J., Jiang, J. H., Yang, Y. T., Yang, X. D., Guo, Z., Qi, Y. P., Zeng, F. H., Zhang, K. L., Chen, N. Z., Xiang, B. D., & Li, L. Q. (2016). Cyclooxygenase-2 expression is associated with initiation of hepatocellular carcinoma, while prostaglandin receptor-1 expression predicts survival. World Journal of Gastroenterology, 22(39), 8798–8805. https://doi.org/10.3748/wjg.v22.i39.8798.CrossRefPubMedPubMedCentral

71.

Chen, G., Li, X., Yang, J., Li, J., Wang, X., He, J., & Huang, Z. (2016). Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis. Archives of Medical Science, 12(5), 1110–1117. https://doi.org/10.5114/aoms.2016.61916. CrossRefPubMed

72.

Li, T., Zhong, J., Dong, X., Xiu, P., Wang, F., Wei, H., et al. (2016). Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the beta-catenin signaling pathway. Oncology Reports, 35(6), 3614–3622. https://doi.org/10.3892/or.2016.4764.CrossRefPubMed

73.

Lin, A., Wang, G., Zhao, H., Zhang, Y., Han, Q., Zhang, C., Tian, Z., & Zhang, J. (2016). TLR4 signaling promotes a COX-2/PGE2/STAT3 positive feedback loop in hepatocellular carcinoma (HCC) cells. Oncoimmunology, 5(2), e1074376. https://doi.org/10.1080/2162402X.2015.1074376.CrossRefPubMed

74.

Huang, M., Wang, L., Chen, J., Bai, M., Zhou, C., Liu, S., et al. (2016). Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1alpha is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery. International Journal of Oncology, 48(5), 2144–2154. https://doi.org/10.3892/ijo.2016.3421.CrossRefPubMedPubMedCentral

75.

Bayomi, E. A., Barakat, A. B., El-Bassuoni, M. A., Talaat, R. M., El-Deftar, M. M., Abdel Wahab, S. A., et al. (2015). Cyclooxygenase-2 expression is associated with elevated aspartate aminotransferase level in hepatocellular carcinoma. Journal of Cancer Research and Therapeutics, 11(4), 786–792. https://doi.org/10.4103/0973-1482.147692.CrossRefPubMed

76.

Guo, Z., Jiang, J. H., Zhang, J., Yang, H. J., Yang, F. Q., Qi, Y. P., Zhong, Y. P., Su, J., Yang, R. R., Li, L. Q., & Xiang, B. D. (2015). COX-2 promotes migration and invasion by the side population of cancer stem cell-like hepatocellular carcinoma cells. Medicine (Baltimore), 94(44), e1806. https://doi.org/10.1097/MD.0000000000001806.CrossRef

77.

Koga, H., Sakisaka, S., Ohishi, M., Kawaguchi, T., Taniguchi, E., Sasatomi, K., Harada, M., Kusaba, T., Tanaka, M., Kimura, R., Nakashima, Y., Nakashima, O., Kojiro, M., Kurohiji, T., & Sata, M. (1999). Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology, 29(3), 688–696. https://doi.org/10.1002/hep.510290355.CrossRefPubMed

78.

Shiota, G., Okubo, M., Noumi, T., Noguchi, N., Oyama, K., Takano, Y., Yashima, K., Kishimoto, Y., & Kawasaki, H. (1999). Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology, 46(25), 407–412.PubMed

79.

Tang, T. C., Poon, R. T., Lau, C. P., Xie, D., & Fan, S. T. (2005). Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World Journal of Gastroenterology, 11(13), 1896–1902.CrossRefPubMedPubMedCentral

80.

Xu, X. M., Deng, J. J., Yuan, G. J., Yang, F., Guo, H. T., Xiang, M., et al. (2011). 5-Lipoxygenase contributes to the progression of hepatocellular carcinoma. Molecular Medicine Reports, 4(6), 1195–1200. https://doi.org/10.3892/mmr.2011.547. PubMedCrossRef

81.

Wang, Q., Zhang, W., Liu, Q., Zhang, X., Lv, N., Ye, L., & Zhang, X. (2010). A mutant of hepatitis B virus X protein (HBxDelta127) promotes cell growth through a positive feedback loop involving 5-lipoxygenase and fatty acid synthase. Neoplasia, 12(2), 103–115.CrossRefPubMedPubMedCentral

82.

Zhang, X., You, X., Wang, Q., Zhang, T., Du, Y., Lv, N., et al. (2012). Hepatitis B virus X protein drives multiple cross-talk cascade loops involving NF-kappaB, 5-LOX, OPN and Capn4 to promote cell migration. PLoS One, 7(2), e31458. https://doi.org/10.1371/journal.pone.0031458.CrossRefPubMedPubMedCentral

83.

You, X., Liu, F., Zhang, T., Li, Y., Ye, L., & Zhang, X. (2013). Hepatitis B virus X protein upregulates oncogene Rab18 to result in the dysregulation of lipogenesis and proliferation of hepatoma cells. Carcinogenesis, 34(7), 1644–1652. https://doi.org/10.1093/carcin/bgt089.CrossRefPubMed

84.

Xu, X. M., Yuan, G. J., Deng, J. J., Guo, H. T., Xiang, M., Yang, F., Ge, W., & Chen, S. Y. (2012). Inhibition of 12-lipoxygenase reduces proliferation and induces apoptosis of hepatocellular carcinoma cells in vitro and in vivo. Hepatobiliary & Pancreatic Diseases International, 11(2), 193–202.CrossRef

85.

Fitian, A. I., Nelson, D. R., Liu, C., Xu, Y., Ararat, M., & Cabrera, R. (2014). Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS. Liver International, 34(9), 1428–1444. https://doi.org/10.1111/liv.12541.CrossRefPubMedPubMedCentral

86.

Panigrahy, D., Kaipainen, A., Greene, E. R., & Huang, S. (2010). Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Reviews, 29(4), 723–735. https://doi.org/10.1007/s10555-010-9264-x.CrossRefPubMedPubMedCentral

87.

Jiang, J. G., Ning, Y. G., Chen, C., Ma, D., Liu, Z. J., Yang, S., Zhou, J., Xiao, X., Zhang, X. A., Edin, M. L., Card, J. W., Wang, J., Zeldin, D. C., & Wang, D. W. (2007). Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Research, 67(14), 6665–6674. https://doi.org/10.1158/0008-5472.CAN-06-3643.CrossRefPubMed

88.

Panigrahy, D., Edin, M. L., Lee, C. R., Huang, S., Bielenberg, D. R., Butterfield, C. E., Barnés, C. M., Mammoto, A., Mammoto, T., Luria, A., Benny, O., Chaponis, D. M., Dudley, A. C., Greene, E. R., Vergilio, J. A., Pietramaggiori, G., Scherer-Pietramaggiori, S. S., Short, S. M., Seth, M., Lih, F. B., Tomer, K. B., Yang, J., Schwendener, R. A., Hammock, B. D., Falck, J. R., Manthati, V. L., Ingber, D. E., Kaipainen, A., D’Amore, P. A., Kieran, M. W., & Zeldin, D. C. (2012). Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. The Journal of Clinical Investigation, 122(1), 178–191. https://doi.org/10.1172/JCI58128.CrossRefPubMed

89.

Schmelzle, M., Dizdar, L., Matthaei, H., Baldus, S. E., Wolters, J., Lindenlauf, N., Bruns, I., Cadeddu, R. P., Kröpil, F., Topp, S. A., Schulte am Esch II, J., Eisenberger, C. F., Knoefel, W. T., & Stoecklein, N. H. (2011). Esophageal cancer proliferation is mediated by cytochrome P450 2C9 (CYP2C9). Prostaglandins & Other Lipid Mediators, 94(1–2), 25–33. https://doi.org/10.1016/j.prostaglandins.2010.12.001.CrossRef

90.

Zhang, D., Lou, J., Zhang, X., Zhang, L., Wang, F., Xu, D., Niu, N., Wang, Y., Wu, Y., & Cui, W. (2017). Hyperhomocysteinemia results from and promotes hepatocellular carcinoma via CYP450 metabolism by CYP2J2 DNA methylation. Oncotarget, 8(9), 15377–15392. https://doi.org/10.18632/oncotarget.14165. PubMedCrossRef

91.

Gong, Z. G., Zhao, W., Zhang, J., Wu, X., Hu, J., Yin, G. C., & Xu, Y. J. (2017). Metabolomics and eicosanoid analysis identified serum biomarkers for distinguishing hepatocellular carcinoma from hepatitis B virus-related cirrhosis. Oncotarget, 8(38), 63890–63900. https://doi.org/10.18632/oncotarget.19173. CrossRefPubMedPubMedCentral

Titel: Bioanalytical insights into the association between eicosanoids and pathogenesis of hepatocellular carcinoma
verfasst von: Yong-Jiang Xu
Zhaojun Zheng
Chen Cao
Jinwei Li
Yuanfa Liu
Publikationsdatum: 22.06.2018
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 2-3/2018
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-018-9747-8

Springer Medizin

Bioanalytical insights into the association between eicosanoids and pathogenesis of hepatocellular carcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2-3/2018

Bioactive lipid metabolism in platelet “first responder” and cancer biology

The role of lipid signaling in the progression of malignant melanoma

Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them

Thrombospondin-1 interactions regulate eicosanoid metabolism and signaling in cancer-related inflammation

Functional link between plasma membrane spatiotemporal dynamics, cancer biology, and dietary membrane-altering agents

Stress, inflammation, and eicosanoids: an emerging perspective

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie